Logo
x

Search

Subscribe Now

severely

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb's Zeposia (ozanimod) Receives CHMP's Positive Opinion for Adult Patients with Moderately to Severely Active U...

  • October 15, 2021
Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from VISIBLE OLE Study for Moderately to Severely Active Ulcerative Colitis

Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from VISIBLE OLE Study for Moderately to Severely Active Ulcer...

  • October 13, 2020
Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

  • August 10, 2020
Gilead and Galapagos Report Results of Filgotinib in P-IIb/III SELECTION Study for Moderately to Severely Active Ulcerative Colitis

Gilead and Galapagos Report Results of Filgotinib in P-IIb/III SELECTION Study for Moderately to Severely Active Ulcerative Coliti...

  • May 21, 2020
Takeda Reports Submission of NDA to MHLW for Vedolizumab SC to Treat Moderately to Severely Active Ulcerative Colitis in Japan

Takeda Reports Submission of NDA to MHLW for Vedolizumab SC to Treat Moderately to Severely Active Ulcerative Colitis in Japan

  • August 9, 2019
Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease

Takeda Reports Results of Entyvio (vedolizumab SC) in P-III VISIBLE 2 Study for Moderately to Severely Active Crohn's Disease

  • July 22, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.